MaxCyte IPO Presentation Deck

Lentiviral ⠀ Delivering Efficient and Reproducible Gene Transfer While Maintaining High Viability and Function Viral Vectors - Adenovial Retroviral Adeno-Associated Viral High tropism for certain cells/tissue Evolved to efficiently delivery DNA into cells Limited payload capacity; difficult to multiplex July 2021 Concerns around random integration and resulting oncogenesis Expensive to manufacture/ industry-wide capacity constraints EP Competitor A expert™ ↑ ↑ New EP Developers Other non-viral methods Non-Viral Delivery Landscape Clinical Support Scale Performance CGMP ↓ CONFIDENTIAL ↑ " ↓ ✓= ↑ * * * * ↓ ↓ * * Description 20 years of development and optimization; cGMP certified; clinically validated; FDA Master Files and Technical Files Academic and research scale instrument; launched and retracted a 25 ml system a few years ago; not CGMP Academic and research scale and/or bolt-on modules; limited performance data around large- scale EP; not cGMP Numerous other early-stage academic processes/ companies in early-stages of development; limited data around viability/scalability; limited commercial operations

View entire presentation